Forte Biosciences Inc Cash Flow Conversion Efficiency
Forte Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Forte Biosciences Inc (FBRX) has a cash flow conversion efficiency ratio of -0.166x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.00 Million) by net assets ($84.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Forte Biosciences Inc (2015–2024)
Cash flow conversion efficiency of Forte Biosciences Inc from 2015 to 2024. This chart illustrates how Forte Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Forte Biosciences Inc for real-time trading data and today's change.
Forte Biosciences Inc Cash Flow Conversion Ratio Explained
Forte Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Forte Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Forte Biosciences Inc ranked by their cash flow conversion efficiency. Also see FBRX stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Canton Strategic Holdings, Inc.
NASDAQ:CNTN
|
-0.005x |
|
Cartesian Therapeutics Inc.
NASDAQ:RNAC
|
0.149x |
|
Takkt AG
XETRA:TTK
|
0.016x |
|
A Plus Asset Advisor Co Ltd
KO:244920
|
0.048x |
|
GAEC Educacao SA
SA:ANIM3
|
-0.007x |
|
Long Table Growth Corp. Class A Ordinary Shares
NASDAQ:LTGR
|
-0.002x |
|
Orvana Minerals Corp.
TO:ORV
|
0.525x |
|
Bursa De Valori Bucuresti SA
RO:BVB
|
0.021x |
Annual Cash Flow Conversion Efficiency for Forte Biosciences Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Forte Biosciences Inc from 2015 to 2024. Review FBRX FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $52.48 Million | $-30.75 Million | -0.586x | +27.93% |
| 2023-12-31 | $35.31 Million | $-28.71 Million | -0.813x | -285.51% |
| 2022-12-31 | $38.82 Million | $-8.19 Million | -0.211x | +47.47% |
| 2021-12-31 | $41.55 Million | $-16.68 Million | -0.401x | -28.50% |
| 2020-12-31 | $58.98 Million | $-18.42 Million | -0.312x | +35.23% |
| 2019-12-31 | $5.75 Million | $-2.77 Million | -0.482x | +18.65% |
| 2018-12-31 | $58.15 Million | $-34.47 Million | -0.593x | -35.35% |
| 2017-12-31 | $71.08 Million | $-31.13 Million | -0.438x | +89.63% |
| 2016-12-31 | $7.00 Million | $-29.54 Million | -4.222x | -684.24% |
| 2015-12-31 | $39.08 Million | $-21.04 Million | -0.538x | -- |
About Forte Biosciences Inc
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. … Read more